Clinical trials · Pennsylvania
WHO Grade III Glioma clinical trials in Pennsylvania
We’re tracking 11 recruiting who grade iii glioma studies with a site in Pennsylvania — including Early Phase 1, Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT04485559RecruitingPhase 1
Testing two drugs for kids and young adults with recurrent gliomas
This trial is testing a combination of two oral drugs, trametinib and everolimus, to see if they can help children and young adults whose glioma (a type of brain tumor) has come back or is growing despite previous treatment. It includes both low-grade and high-grade gliomas, and aims to stop the tumor from growing.
Philadelphia, PennsylvaniaAges 1–25 - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
Philadelphia, PennsylvaniaAges 2–21 - NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Philadelphia, PennsylvaniaAges 2–39 - NCT05553041RecruitingEarly Phase 1
PET-MRI scan test for aggressive brain tumors in children
This early-phase study uses a special PET scan plus MRI to help doctors tell apart tumor changes in children with aggressive gliomas. It may help find whether treatment is working or if the tumor is progressing, while also mapping tumor activity in the brain.
Philadelphia, PennsylvaniaAges 1–21 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Philadelphia, PennsylvaniaAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Philadelphia, PennsylvaniaAges 1–39 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Philadelphia, PennsylvaniaAges 12–39 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Philadelphia, PennsylvaniaAges 1–21 - NCT04655404RecruitingEarly Phase 1
Larotrectinib for children with newly diagnosed glioma with NTRK fusion
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Philadelphia, PennsylvaniaAges Up to 21 years - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Philadelphia, PennsylvaniaAges 4–39 - NCT05096481RecruitingPhase 2
Vaccine trial for children with certain brain tumors
This Phase 2 study tests a vaccine made to target CMV (a virus) in order to treat children with medulloblastoma or newly diagnosed high-grade glioma/DIPG. If you’re eligible, you’d receive the study vaccine and the team would closely watch how well it’s tolerated and how your cancer responds.
Philadelphia, PennsylvaniaAges 3–39
WHO Grade III Glioma trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting who grade iii glioma studies listed above.
- Children's Hospital of Philadelphia · 11 studies
What taking part in a who grade iii glioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
WHO Grade III Glioma trials in other states
Common questions
- Are there who grade iii glioma clinical trials in Pennsylvania?
- Yes. We're currently tracking 11 recruiting who grade iii glioma studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a who grade iii glioma study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a who grade iii glioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New who grade iii glioma studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.